scholarly article | Q13442814 |
P356 | DOI | 10.1093/RHEUMATOLOGY/KEW061 |
P698 | PubMed publication ID | 27330161 |
P50 | author | Janet Pope | Q48742471 |
Carol Hitchon | Q89451273 | ||
Vivian P Bykerk | Q91352262 | ||
Boulos Haraoui | Q113411649 | ||
P2093 | author name string | Gilles Boire | |
Diane Tin | |||
Carter Thorne | |||
Shahin Jamal | |||
Ed Keystone | |||
CATCH investigators | |||
P2860 | cites work | So depression is an inflammatory disease, but where does the inflammation come from? | Q21245291 |
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis | Q30860792 | ||
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states | Q33222832 | ||
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature | Q33387149 | ||
Cardiovascular morbidity and mortality in rheumatoid arthritis | Q33806651 | ||
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q34130671 | ||
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment | Q34563216 | ||
Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis | Q34730116 | ||
Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES) | Q35023431 | ||
Increased risk for chronic comorbid disorders in patients with inflammatory arthritis: a population based study | Q35074573 | ||
Does the microbiota play a role in the pathogenesis of autoimmune diseases? | Q35443254 | ||
Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study | Q35617716 | ||
Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative | Q36001551 | ||
Mechanisms of disease: atherosclerosis in autoimmune diseases | Q36577423 | ||
Comorbidities in rheumatoid arthritis | Q36942648 | ||
Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis | Q37177578 | ||
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). | Q37465556 | ||
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. | Q37883018 | ||
From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis? | Q38123798 | ||
Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort | Q38185644 | ||
Immune mechanisms linked to depression via oxidative stress and neuroprogression | Q38315020 | ||
Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs | Q38471394 | ||
Can comorbidity be measured by questionnaire rather than medical record review? | Q40940629 | ||
Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease | Q44051899 | ||
Long-term physical functioning and its association with somatic comorbidity and comorbid depression in patients with established rheumatoid arthritis: a longitudinal study | Q44264105 | ||
The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity | Q44353678 | ||
Validation of a self-report comorbidity questionnaire for multiple sclerosis | Q44809985 | ||
Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort | Q44844209 | ||
Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort | Q45769410 | ||
Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis | Q48069664 | ||
Psychiatric and cardiovascular comorbidities as causes of long-term work disability among individuals with recent-onset rheumatoid arthritis. | Q50616014 | ||
Co-morbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up. | Q51227331 | ||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | comorbidity | Q1414874 |
P304 | page(s) | 1751-1762 | |
P577 | publication date | 2016-06-21 | |
P1433 | published in | Rheumatology | Q7320492 |
P1476 | title | Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort | |
P478 | volume | 55 |
Q90587274 | Combination of COX-2 inhibitor and metformin attenuates rate of admission in patients with rheumatoid arthritis and diabetes in Taiwan |
Q50041216 | Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis |
Q39371685 | Novel treatment strategies in rheumatoid arthritis. |
Q93037024 | Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial |
Q89379251 | Rheumatoid arthritis: TNF inhibitors and cardiovascular risk management in RA |
Q89770369 | Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis |
Search more.